NASDAQ:CCCC - C4 Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.50
  • Forecasted Upside: 32.33 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$36.65
▼ -1.17 (-3.09%)

This chart shows the closing price for CCCC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New C4 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CCCC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CCCC

Analyst Price Target is $48.50
▲ +32.33% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for C4 Therapeutics in the last 3 months. The average price target is $48.50, with a high forecast of $63.00 and a low forecast of $20.00. The average price target represents a 32.33% upside from the last price of $36.65.

This chart shows the closing price for CCCC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in C4 Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2021Bank of AmericaInitiated CoverageBuy$54.00High
10/14/2021SVB LeerinkInitiated CoverageMarket Perform$20.00High
9/29/2021Stifel NicolausInitiated CoverageHold$45.00High
6/25/2021Brookline Capital ManagementReiterated RatingBuyHigh
6/24/2021Brookline Capital AcquisitionInitiated CoverageBuy$54.00Low
6/22/2021BMO Capital MarketsBoost Price TargetOutperform$53.00 ➝ $55.00Medium
6/4/2021HC WainwrightInitiated CoverageBuy$63.00High
3/31/2021BMO Capital MarketsInitiated CoverageOutperform$55.00High
12/8/2020BMO Capital MarketsBoost Price TargetOutperform$33.00 ➝ $45.00Medium
10/28/2020UBS GroupInitiated CoverageBuyHigh
10/27/2020Jefferies Financial GroupInitiated CoverageBuy$34.00High
10/27/2020BMO Capital MarketsInitiated CoverageOutperform$33.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
C4 Therapeutics logo
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $36.65
Low: $35.95
High: $38.01

50 Day Range

MA: $44.80
Low: $36.65
High: $50.50

52 Week Range

Now: $36.65
Low: $27.25
High: $51.21

Volume

189,016 shs

Average Volume

330,676 shs

Market Capitalization

$1.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of C4 Therapeutics?

The following sell-side analysts have issued reports on C4 Therapeutics in the last twelve months: Bank of America Co., BMO Capital Markets, Brookline Capital Acquisition Corp., Brookline Capital Management, HC Wainwright, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CCCC.

What is the current price target for C4 Therapeutics?

6 Wall Street analysts have set twelve-month price targets for C4 Therapeutics in the last year. Their average twelve-month price target is $48.50, suggesting a possible upside of 32.3%. HC Wainwright has the highest price target set, predicting CCCC will reach $63.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $20.00 for C4 Therapeutics in the next year.
View the latest price targets for CCCC.

What is the current consensus analyst rating for C4 Therapeutics?

C4 Therapeutics currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CCCC will outperform the market and that investors should add to their positions of C4 Therapeutics.
View the latest ratings for CCCC.

How do I contact C4 Therapeutics' investor relations team?

The company's listed phone number is 617-231-0700 and its investor relations email address is [email protected] The official website for C4 Therapeutics is www.c4therapeutics.com.